» Articles » PMID: 27147525

Nutraceuticals in Parkinson's Disease

Overview
Specialty Biochemistry
Date 2016 May 6
PMID 27147525
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Current pharmacological strategies for Parkinson's disease (PD), the most common neurological movement disorder worldwide, are predominantly symptom relieving and are often plagued with undesirable side effects after prolonged treatment. Despite this, they remain as the mainstay treatment for PD due to the lack of better alternatives. Nutraceuticals are compounds derived from natural food sources that have certain therapeutic value and the advent of which has opened doors to the use of alternative strategies to tackle neurodegenerative diseases such as PD. Notably, nutraceuticals are able to position themselves as a "safer" strategy due to the fact that they are naturally derived compounds, therefore possibly having less side effects. Significant efforts have been put into better comprehending the role of nutraceuticals in PD, and we will look at some of them in this review. Broadly speaking, these compounds execute their positive effects via modulating signalling pathways, inhibiting oxidative stress, inflammation and apoptosis, as well as regulating mitochondrial homoeostasis. Importantly, we will highlight how a component of green tea, epigallocatechin-3-gallate (EGCG), confers neuroprotection in PD via its ability to activate AMP kinase and articulate how its beneficial effects in PD are possibly due to enhancing mitochondrial quality control.

Citing Articles

Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential.

Capasso L, De Masi L, Sirignano C, Maresca V, Basile A, Nebbioso A Molecules. 2025; 30(3).

PMID: 39942757 PMC: 11821029. DOI: 10.3390/molecules30030654.


Comprehensive Review of Nutraceuticals against Cognitive Decline Associated with Alzheimer's Disease.

Reza-Zaldivar E, Jacobo-Velazquez D ACS Omega. 2023; 8(39):35499-35522.

PMID: 37810693 PMC: 10552500. DOI: 10.1021/acsomega.3c04855.


Therapeutic Activity of Green Tea Epigallocatechin-3-Gallate on Metabolic Diseases and Non-Alcoholic Fatty Liver Diseases: The Current Updates.

James A, Wang K, Wang Y Nutrients. 2023; 15(13).

PMID: 37447347 PMC: 10346988. DOI: 10.3390/nu15133022.


Clinical Benefits of Therapeutic Interventions Targeting Mitochondria in Parkinson's Disease Patients.

Ciocca M, Pizzamiglio C CNS Neurol Disord Drug Targets. 2023; 23(5):554-561.

PMID: 37005519 PMC: 11071650. DOI: 10.2174/1871527322666230330122444.


Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy.

Colletti A, Fratter A, Pellizzato M, Cravotto G Nutrients. 2022; 14(22).

PMID: 36432457 PMC: 9696395. DOI: 10.3390/nu14224769.


References
1.
Anderson D, Bradbury K, Schneider J . Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism. Eur J Neurosci. 2008; 28(3):610-7. DOI: 10.1111/j.1460-9568.2008.06356.x. View

2.
Chao J, Yu M, Ho Y, Wang M, Chang R . Dietary oxyresveratrol prevents parkinsonian mimetic 6-hydroxydopamine neurotoxicity. Free Radic Biol Med. 2008; 45(7):1019-26. DOI: 10.1016/j.freeradbiomed.2008.07.002. View

3.
Nevado J, Sanz R, Sanchez-Rodriguez C, Garcia-Berrocal J, Martin-Sanz E, Gonzalez-Garcia J . Ginkgo biloba extract (EGb761) protects against aging-related caspase-mediated apoptosis in rat cochlea. Acta Otolaryngol. 2010; 130(10):1101-12. DOI: 10.3109/00016481003713657. View

4.
Shi C, Zhao L, Zhu B, Li Q, Yew D, Yao Z . Dosage effects of EGb761 on hydrogen peroxide-induced cell death in SH-SY5Y cells. Chem Biol Interact. 2009; 180(3):389-97. DOI: 10.1016/j.cbi.2009.04.008. View

5.
Hwang J, Kwon D, Yoon S . AMP-activated protein kinase: a potential target for the diseases prevention by natural occurring polyphenols. N Biotechnol. 2009; 26(1-2):17-22. DOI: 10.1016/j.nbt.2009.03.005. View